Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients.

We investigated the effect of unexpected N2 on survival in stage IIIB/N2 cases. We retrospectively analyzed 1803 non-small cell lung cancer patients between 2010 and 2016. There were 89 patients (4.9%) with unexpected N2 (pathological (p) IIIB/N2 group), whereas 49 patients (2.7%) with cN2 (clinical (c) IIIB/N2 group). Although pIIIB/N2 group underwent surgery followed by adjuvant therapy, the cIIIB/N2 group of patients had multimodality treatment including induction chemotherapy ± radiotherapy followed by surgery. The five-year overall survival (OS) for all patients was 36.0% [median survival time (MST) 27.9 months], and disease-free survival (DFS) was 28.9% (MST, 18.2 months). The OS was 39.6% (MST: 34.4 months) and the median DFS time was 31.1% (Median: 23.1 months) in the pIIIB/N2 group, whereas it was 29.2% (MST: 23.0 months) for OS and 22% (median: 12.4 months) for DFS in the cIIIB/N2 group. There were no significant OS and DFS differences between the pIIIB/N2 group and the cIIIB/N2 group (p = 0.124 and p = 0.168, respectively). In stage IIIB/N2 cases, the fact that N2 could not be detected preoperatively with minimally invasive or invasive methods and was detected in the pathological examination after surgery does not provide a survival advantage.

Citation

Volkan Erdoğu, Necati Çıtak, Celal Buğra Sezen, Dilekhan Kizir, Gamze Tanrıkulu, Mustafa Vedat Doğru, Yunus Seyrek, Levent Cansever, Özkan Saydam, Muzaffer Metin. Survival impact of unexpected N2 in stage IIIB/N2 non-small cell lung cancer patients. Asian cardiovascular & thoracic annals. 2023 Mar;31(3):238-243

Mesh Tags

PMID: 36683332

search → result